

Clinical Trial Protocol

Iranian Registry of Clinical Trials

26 Jun 2026

Aspirin as an augmenting to citlaopram for treating major depressive disorder, a randomized double blind placebo controlled clinical trial

Protocol summary

Summary

This 6 week randomized controlled clinical trial investigates the safety and efficacy of Aspirin as an augmentation with citalopram for treating patients with major depressive disorder. This study includes 60 patients. One group receives citalopram plus aspirin and the other group receives citalopram plus placebo. Hamilton Depression rating scale is used to measure the outcome. The patients will be assessed at baseline, week 2, and week 6.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT201306203930N27**
Registration date: **2013-07-16, 1392/04/25**
Registration timing: **registered_while_recruiting**

Last update:

Update count: **0**

Registration date

2013-07-16, 1392/04/25

Registrant information

Name

Ahmad Ghanizadeh

Name of organization / entity

Research Center for Psychiatry and Behavioral Sciences, Shiraz University Of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 71 1627 3070

Email address

ghanizad@sina.tums.ac.ir

Recruitment status

Recruitment complete

Funding source

Shiraz University of Medical Sciences

Expected recruitment start date

2013-06-17, 1392/03/27

Expected recruitment end date

2014-06-17, 1393/03/27

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Aspirin as an augmenting to citalopram for treating major depressive disorder, a randomized double blind placebo controlled clinical trial

Public title

Aspirin for treating depression, a randomized double blind controlled clinical trial

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: patients with major depressive disorder according to DSM-VI, both gender, and aged between 17 and 70 years old. Exclusion criteria: receive NSAIDs concurrently, reported positive history of cancer, serious medical condition, and hypothyroidism.

Age

From **17 years** old to **70 years** old

Gender

Both

Phase

2

Groups that have been masked

No information

Sample size

Target sample size: **60**

Randomization (investigator's opinion)

Randomized
Randomization description
Blinding (investigator's opinion)
Double blinded
Blinding description
Placebo
Used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Shiraz University of Medical Sciences
Street address
Shiraz University of Medical Sciences
City
Shiraz
Postal code
--

Approval date
2013-06-16, 1392/03/26
Ethics committee reference number
Ct-P-92-5713

Health conditions studied

1

Description of health condition studied
Major Depressive disorder
ICD-10 code
F30-39
ICD-10 code description
Depressive episode

Primary outcomes

1

Description
Hamilton Derepression Rating Scale
Timepoint
baseline, 2 week, and 6 week
Method of measurement
Interveiwe

Secondary outcomes

empty

Intervention groups

1

Description
Citalopram 20mg/day+Aspirin (160mg/day) for 6 weeks
Category
Treatment - Drugs

2

Description
Citalopram 20mg/day+Placebo for 6 weeks
Category
Placebo

Recruitment centers

1

Recruitment center
Name of recruitment center
Research Center for Psychiatry and Behavioral Sciences, Shiraz University of Medical Sciences
Full name of responsible person
Ahmad Ghanizadeh
Street address
Hafez Hospital
City
Shiraz

2

Recruitment center
Name of recruitment center
Fasa University of Medical sciences
Full name of responsible person
Street address
City
Fasa

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Vice chancellor for research, Shiraz University of Medical Sciences
Full name of responsible person
Gholam Reza Hatam
Street address
Vice-chancellery of Research Affairs, Shiraz University of Medical sciences, Zand Street
City
Shiraz
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Vice chancellor for research, Shiraz University of Medical Sciences
Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

Person responsible for general inquiries

Contact

Name of organization / entity

Shiraz University of Medical sciences

Full name of responsible person

Ahmad Ghanizadeh

Position

Professor of Psychiatry

Other areas of specialty/work

Street address

Hafez Hospital

City

Shiraz

Postal code

Phone

+98 71 1235 7282

Fax

Email

ghanizad@sina.tums.ac.ir

Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity

Shiraz University of Medical sciences

Full name of responsible person

Ahmad Ghanizadeh

Position

Professor of Psychiatry

Other areas of specialty/work

Street address

Hafez Hospital

City

Shiraz

Postal code

Phone

+98 71 1627 3070

Fax

Email

ghanizad@sina.tums.ac.ir

Web page address

Person responsible for updating data

Contact

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty